Biotechnology · Healthcare
CEO, CFO, Board Member
2018-01-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Lineage Cell Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LCTX alertsBrian M. Culley is recorded as CFO at Lineage Cell Therapeutics, Inc. (LCTX) since July 8, 2022, Board Member at Lineage Cell Therapeutics, Inc. (LCTX) since January 1, 2018 and CEO at Lineage Cell Therapeutics, Inc. (LCTX). The newest filing on record that lists Brian M. Culley as Board Member at Lineage Cell Therapeutics, Inc. (LCTX) is dated April 29, 2026. Lineage Cell Therapeutics, Inc. reported in an 8-K filed September 7, 2023 a re-election or new board role (director) for Brian M. Culley, on the board since at least 2018, effective September 6, 2023. Lineage Cell Therapeutics, Inc. reported in an 8-K filed July 7, 2022 that Brian M. Culley was appointed interim Chief Financial Officer, effective July 8, 2022. Lineage Cell Therapeutics, Inc. reported in an 8-K filed January 20, 2021 that Brian M. Culley was appointed interim Chief Financial Officer, effective January 20, 2021. The proxy statement of Lineage Cell Therapeutics, Inc. reports total compensation of $1,349,913 for Brian M. Culley in fiscal 2020, including a base salary of $551,900. Disclosed compensation is on record for 3 fiscal years. Brian M. Culley has spoken on 24 earnings calls across 1 company, most recently for Lineage Cell Therapeutics, Inc. on November 12, 2026. Lineage Cell Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lineage Cell Therapeutics, Inc. includes Jill A. Howe (CFO and Board Member), Kevin L. Cook (CFO), Alexandra Hernandez (Chief Accounting Officer) and 7 others.
“The Company’s shareholders elected the nine nominees named below to the Company’s board of directors to hold office until the Company’s 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
“Effective July 8, 2022, Brian M. Culley, Lineage's Chief Executive Officer, will serve as Lineage's interim Chief Financial Officer and principal financial officer,”
“To what I expect will be an important and memorable earnings call. Just a few minutes ago, we announced that we had acquired NeuroAirmid Therapeutics, a private biotech company founded on technology licensed from the lab of world-leading Huntington's disease researcher, Dr. Leslie Thompson.”
“We appreciate you taking the time to join us today. As some of you know, from time to time, I like to use these calls to bring investors behind the scenes to better understand how we are advancing our programs and business.”
“We appreciate you taking the time to join us today. We have a lot of great things to cover. I'm going to try and keep it short so that we can have plenty of time for analyst questions.”
“We appreciate you taking the time to join us on the call today. We have a great call planned, highlighted by recent warrant exercises that further extend our runway, and a positive result for our initial go-no-go development milestone in our islet cell research initiative.”
“We appreciate you taking the time to join us on the call today. I'll begin with an update on our lead program, Oprygen, then review our progress against the five strategic goals which I outlined for you last quarter.”
2022-07-08–present
2018-01-01–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CEO, CFO, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Lineage Cell Therapeutics, Inc. (LCTX) | CEO | $551,900 | $1,349,913 |
| 2019 | Lineage Cell Therapeutics, Inc. (LCTX) | CEO | $535,800 | $772,742 |
| 2018 | Lineage Cell Therapeutics, Inc. (LCTX) | CEO | $154,923 | $2,862,707 |